Skip to content

Fugal Infection in COVID-19 Patients

Invasive Fungal Sinusitis Among Post COVID-19 Survivors in Upper Egypt

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04914013
Enrollment
50
Registered
2021-06-04
Start date
2021-06-30
Completion date
2021-09-30
Last updated
2021-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

COVID-19, invasive fungal infection

Brief summary

Screening early detection of invasive fungal sinusitis in COVID-19 positive patients

Detailed description

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); the causative organism of Coronavirus disease 2019 (Covid-19); infects primarily the lungs leading to more than 100 million COVID-19 cases around the world, resulting in almost three million deaths. Covid-19 spectrum of symptoms expanded from upper respiratory tract infection to extensive viral pneumonia and respiratory failure. Covid-19 patients are highly susceptible to superimposed secondary infection especially fungal infections. Acute invasive fungal sinusitis (AIFS) is one of the most aggressive forms of sinusitis that is commonly present in immunocompromised patients and frequently leads to significant mortality and morbidity. Mucormycosis a life threatening AIFS characterized by hyphal invasion and massive destruction of maxillofacial structures. Histological characters include mycotic infiltration of vessels with propensity to tissue infarction. In addition to other fungi such as Acinetobacter, Klebsiella, Enterobacter, Aspergillus and Candida that frequently lead to secondary fungal infection in Covid-19 patients. The co-existence of Covid-19 and AIFS is due to immune dysregulation in Covid-19 patients as both CD4+ and CD8+ T lymphocytes are suppressed thus impair patients' innate immunity. In addition to the extensive use of steroids, broad spectrum antibiotics and monoclonal antibodies may contribute in fungal infection. Covid-19 patients with pre-existing conditions such as untreated HIV, organ transplantation, un controlled diabetes and malignancies are more susceptible to AIFS on the contrary Covid-19 patients with underlying chronic disease such as hypertension, chronic kidney and chronic heart disease usually are not associated with more risk of AIFS. Taking in consideration raised incidence of morbidity and mortality associated with AIFS and on the other hand limited studies available especially in middle east region raised the importance of studying the incidence and the behaviour of AIFS in Covid-19 patients. This study aims to To assess the occurrence of AIFS superinfections in patients with Covid-19.

Interventions

OTHERno intervention

no intervention

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patients who were diagnosed with invasive fungal sinusitis, and are survivors of Covid19 infection, all cases diagnosed on the basis of the interim guidance of the World Health Organization (WHO) for diagnosis of SARS-CoV-2.

Exclusion criteria

* \- Patients who received antifungal therapy within three days prior to sample collection. * Patients refused to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
detection of invasive fungal sinusitis after covid 19 infection.baselinediagnosis of invasive fungal post COVID-19 infection

Secondary

MeasureTime frameDescription
Identify specific fungi that participate in IFS1 monthspecify by culture and sensitivity fungi that participate in invasive fungal sinusitis after covid 19 infection

Contacts

Primary ContactMaiada Hashem
maiada.hashem@aun.edu.eg01006559662
Backup ContactAliae Mohamed-Hussien
aliaehussein@aun.edu.eg01222302352

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026